![Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet](https://www.thelancet.com/cms/attachment/a94a0d96-3434-4a33-8926-adff3b15c63f/gr2_lrg.gif)
Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet
![Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies - ScienceDirect Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1558767317302744-gr1.jpg)
Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies - ScienceDirect
![SQL Query to Find Names of the Employees Whose Department Have Number of Employees Less than 2 - GeeksforGeeks SQL Query to Find Names of the Employees Whose Department Have Number of Employees Less than 2 - GeeksforGeeks](https://media.geeksforgeeks.org/wp-content/uploads/20211226190223/WhatsAppImage20211226at185115.jpeg)
SQL Query to Find Names of the Employees Whose Department Have Number of Employees Less than 2 - GeeksforGeeks
![A cluster randomised controlled trial of a web-based youth mental health service in Australian schools - The Lancet Regional Health – Western Pacific A cluster randomised controlled trial of a web-based youth mental health service in Australian schools - The Lancet Regional Health – Western Pacific](https://www.thelancet.com/cms/attachment/dbdaf5ad-286b-4785-bfd6-416c816806ef/gr1_lrg.jpg)
A cluster randomised controlled trial of a web-based youth mental health service in Australian schools - The Lancet Regional Health – Western Pacific
![Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial - The Lancet Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial - The Lancet](https://www.thelancet.com/cms/asset/f45d0ad9-b10b-4adb-88fc-8a81218701e1/gr1.jpg)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial - The Lancet
![PDF) Phonetic Realization of Focus with no On-Focus Pitch Range Expansion in Turkish | Canan Ipek - Academia.edu PDF) Phonetic Realization of Focus with no On-Focus Pitch Range Expansion in Turkish | Canan Ipek - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/40513607/mini_magick20190220-9355-1xh2jn5.png?1550731868)
PDF) Phonetic Realization of Focus with no On-Focus Pitch Range Expansion in Turkish | Canan Ipek - Academia.edu
![Three randomized controlled trials evaluating the impact of “spin” in health news stories reporting studies of pharmacologic treatments on patients'/caregivers' interpretation of treatment benefit | BMC Medicine | Full Text Three randomized controlled trials evaluating the impact of “spin” in health news stories reporting studies of pharmacologic treatments on patients'/caregivers' interpretation of treatment benefit | BMC Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12916-019-1330-9/MediaObjects/12916_2019_1330_Fig1_HTML.png)
Three randomized controlled trials evaluating the impact of “spin” in health news stories reporting studies of pharmacologic treatments on patients'/caregivers' interpretation of treatment benefit | BMC Medicine | Full Text
A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials | PLOS ONE
![Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies - ScienceDirect Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1558767317302744-gr2.jpg)
Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies - ScienceDirect
![Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial - The Lancet Infectious Diseases Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/313bc4ef-303b-4810-b2c9-d46dc3d3bb40/gr1.gif)
Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial - The Lancet Infectious Diseases
![MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study | Nature Medicine MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01336-3/MediaObjects/41591_2021_1336_Fig1_HTML.png)
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study | Nature Medicine
![A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial | Annals of the Rheumatic A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial | Annals of the Rheumatic](https://ard.bmj.com/content/annrheumdis/79/1/123/F1.large.jpg)